Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Inclusion Criteria: * Diagnosis of platinum-sensitive recurrence of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer * The following histologic subtypes are eligible: papillary serous, endometrioid, mucinous, clear cell, adenocarcinomas, transitional, and mixtures of the above. * At least one measurable lesion according to RECIST criteria via CT or MRI scan * Received a platinum-containing regimen at initial diagnosis * ECOG performance status of 0,1 or 2 * 18 years of age or older * Life expectancy of greater than 12 weeks * WBC \> 1,500/mm3 * Neutrophils \> 1,500/mm3 * Platelets \> 100,000/mm3 * Total Bilirubin \< 1.5 ULN * Calculated creatinine clearance \> 45 ml/min * ALT/AST \< 3 x ULN (no liver mets) ALT/AST \< 5 x ULN (with liver mets) * Complete recovery from completion of previous chemotherapy or biologic therapy * Negative pregnancy test and agree to practice effective method of birth control Exclusion Criteria: * Patients with sarcomatous, stromal, or germ cell elements * Prior pelvic radiotherapy \> 25% of bone marrow * Uncontrolled medical problem that in the opinion of the investigator would preclude safe administration of the study drugs * Past history of bone marrow transplantation or stem cell support * Known history of CNS metastasis unless the patient has had treatment with surgery or radiation therapy, is neurologically stable, and does not require oral or intravenous corticosteroids or anticonvulsants * Prior malignancy except adequately treated carcinoma in situ of the uterine cervix, incidental stage I endometrial cancer, basal cell or squamous cell skin cancer or breast cancer (invasive or ductal carcinoma in situ) of which the patient has been disease-free for at least five years * Routine prophylactic use of G-CSF or GM-CSF or blood transfusions within 2 weeks * Clinically significant cardiac disease as defined by: history of unstable angina within 6 months; history of symptomatic ventricular arrhythmias; history of congestive heart failure; history of myocardial infarction within 6 months * Uncontrolled hypercalcemia or diabetes mellitus * Any signs of intestinal obstruction with bowel function and/or nutrition * Grade 2 or greater peripheral neuropathy * Participation in an investigational study within three weeks * History of anaphylactic shock to prior platinum chemotherapy * History of psychiatric disability or other central nervous system disorder